| 초록 |
Background: Interstitial tonicity increases vascular endothelial growth factor-C (VEGF-C), a lymphangiogenic factor,
in salt-induced hypertension. Therefore, it can be assumed that changes of serum VEGF-C level may be associated
with increasing blood pressure. However, there is no report about the changes of serum VEGF-C levels in patients
with chronic kidney disease (CKD). The aims of this study were to investigate the changes of serum and urine VEGFC
levels in CKD stage 3-4 patients, and to evaluate the relationship between blood pressure and serum VEGF-C levels
in the CKD stage 5 patients with hemodialysis.
Methods: Glomerular filtration rate (GFR) was assessed by the MDRD equation. Blood pressure and VEGF-C levels
(serum and urine) were measured by enzyme linked immunosorbant assay (ELISA) in 9 patients with stage 3-4 CKD,
41 hemodialysis patients and in 8 healthy individuals. The study also evaluated the relationship between serum
VEGF-C levels and stage of blood pressure.
Results: The mean systolic and diastolic blood pressures of stage 3-4 CKD and hemodialysis patients were significantly
higher than that of the healthy controls. The mean serum level of VEGF-C in stage 3-4 CKD and stage 5 hemodialysis
patients significantly decreased when compared to healthy subjects (202.3±204.0 pg/mL in stage 3-4 CKD, 425.4±
943.7 in hemodialysis patient, 4,913±5,786 in control; p value <0.05). The urine VEGF- C (pg) per urine creatinine
(mg) were significantly increased in stage 3-4 CKD patients compared with healthy controls (35.8±9.8 ng of urine
VEGF-C per mg of urine creatinine to stage 3-4 CKD patients, 177.0±113.5 to healthy controls; p value<0.01). The
fractional excretion of VEGF-C was also increased in patients with stage 3-4 CKD compared with healthy controls
(6.43±6.25% to stage 3-4 CKD patients and 0.01±0.02 to healthy controls; p value<0.01). For 41 hemodialysis
patients, the concentrations of serum VEGF-C in patients with stage 1 hypertension (98.60 +/- 26.99 pg/ml) or stage
2 hypertension tended to be higher than those in healthy controls (80.44 +/- 24.57), but the differences did not
reach statistical significance. The serum levels of VEGF-C in patients with CKD stage 5 were not correlated with the
number of anti-hypertensive drugs used.
Conclusion: We suggest that circulating levels of VEGF-C were decreased in patient with CKD. The decrease of
VEGF-C in stage 3-4 CKD patients coincided with an increase in the uri |